

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT5751724

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
JEIL PHARMACEUTICAL CO., LTD.	08/11/2019
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	S.BIOMEDICS CO., LTD.
<b>Street Address:</b>	4TH FLOOR, 28, SEONGSUI-RO 26-GIL
<b>Internal Address:</b>	SEONGDONG-GU
<b>City:</b>	SEOUL
<b>State/Country:</b>	KOREA, REPUBLIC OF
<b>Postal Code:</b>	04797
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	16474662
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(212)808-0844
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	212-808-0700
<b>Email:</b>	jarcher@norris-law.com
<b>Correspondent Name:</b>	KURT G. BRISCOE
<b>Address Line 1:</b>	NORRIS MCLAUGHLIN P.A.
<b>Address Line 2:</b>	875 THIRD AVENUE - 8TH FLOOR
<b>Address Line 4:</b>	NEW YORI, NEW YORK 10022
<b>ATTORNEY DOCKET NUMBER:</b>	12779-5 KGB
<b>NAME OF SUBMITTER:</b>	KURT G. BRISCOE
<b>SIGNATURE:</b>	/Kurt G. Briscoe/
<b>DATE SIGNED:</b>	10/03/2019
<b>Total Attachments: 1</b>	
source=Executed_Assignment#page1.tif	

**ASSIGNMENT**

For valuable consideration, the receipt and adequacy of which is hereby acknowledged, we **JEIL PHARMACEUTICAL CO., LTD.**, a corporation of Korea, located at 343, Sapyeong-daero Seocho-gu Seoul 06543, Republic of Korea (hereinafter "assignor") being the sole owner of the following United States patent(s):

**U.S. Patent Application No. 16/474,662, Filed June 28, 2019**

hereby sells, assigns and transfers unto:

**S.BIOMEDICS CO., LTD.**  
4th Floor, 28, Seongsui-ro 26-gil  
Seongdong-gu, Seoul 04797  
Republic of Korea

a corporation of Korea, (hereinafter "assignee"), its successors, legal representatives and assigns, the entire right, title, and interest in and to the said Letters Patent aforesaid; to the full end of the term for which said Letters Patent are granted, as fully and entirely as the same would have been held by assignor had this assignment and sale not been made.

**JEIL PHARMACEUTICAL CO., LTD.,**

By: Tae Soo Won  
Name: Tae Soo Won  
Title: Executive Managing Director

Date: Aug 13, 2019

By: [Signature]  
Name: Myung Soo Cho  
Title: Managing Director

Date: Aug 16, 2019